KymaThera closed an $80 million Series B led by Alta Partners to advance its PI3Kα inhibitor K-1728 toward clinical development.
- Amount
- $80M
- Stage
- Series B
- Announced
- 6 October 2026
- Lead
- Alta Partners
- Other investors
- Venrock, Foresite Capital, J. Wood Capital
- Use of funds
- Primarily advancing K-1728 development through initial clinical proof-of-concept
- Total raised
- $100M to date
- Checked
- Announced by the company